EdRIP raising €200M for new life sciences VC fund
This article was originally published in Scrip
Four years after closing the BioDiscovery 3 at €156 million, Edmond de Rothschild Investment Partners is now on the road raising a €200 million fourth fund to invest innovative European life sciences companies. The French venture capitalist started fundraising three weeks ago and is confident that it will be able to complete a first closing at more than €100 million by the end of April or early May.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.